euro adhoc: Sartorius AG / Financial Figures/Balance Sheet / Group sales revenue rose 9.2% / EBITDA improved 18.1% to EUR49.3 million / EBIT up 26.4% to EUR35.0 million / Earnings per share rose from

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc. The issuer is responsible
for the content of this announcement.
--------------------------------------------------------------------------------

17.10.2006

During the first nine months of fiscal 2006, sales revenue of the
Sartorius Group rose 9.2% (currency-adjusted: +9.0%) to EUR386.0
million (previous year: EUR353.5 mn). In the Biotechnology Division,
sales revenue climbed 10.1% (currency-adjusted: +9.9%) to EUR203.7
million (previous year: EUR185.0 mn); in the Mechatronics Division,
8.2% (currency-adjusted: +8.1%) to EUR182.3 million (previous year:
EUR168.5 mn). Primarily because of the positive development in the
Mechatronics Division, Group order intake grew 3.9%
(currency-adjusted: +3.7%) to EUR379.4 million (previous year:
EUR365.3 mn).

Group earnings before interest, taxes, depreciation and amortization
(EBITDA) increased 18.1% to EUR49.3 million (previous year: EUR41.7
mn). Earnings before interest and taxes (EBIT) surged 26.4% to
EUR35.0 million (EUR27.7 mn); as a result, the EBIT margin improved
from 7.8% to 9.1%. For the Biotechnology Division, EBIT soared 42.2%
from EUR16.2 million to EUR23.1 million, whereas for the Mechatronics
Division, EBIT at EUR11.9 million was slightly higher than the
year-earlier figure (EUR11.4 mn) and already included nearly all the
full-year 2006 costs budgeted for the expansion of Sartorius
locations in China, India and Germany. Net profit shot up 39.4% to
EUR18.9 million (EUR13.5 mn); accordingly, earnings per share were
EUR1.11 (EUR0.79). In comparison to the previous year, capital
expenditures roughly doubled to EUR20.4 million (EUR10.0 mn). Net
cash flow at EUR10.6 million (EUR15.8 mn) was significantly positive.

The company confirms its targets of increasing full-year sales
revenue by approximately 7% in constant currencies and of achieving
an EBIT of about 10% of sales revenue, as concretized after the first
half. In fiscal 2007, the company intends to continue its growth
trend and increase the profitability of the Sartorius Group to an
EBIT of 11% of sales revenue.

end of announcement euro adhoc 17.10.2006 20:55:44
--------------------------------------------------------------------------------

ots Originaltext: Sartorius AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:
Andreas Wiederhold
Phone +49.551.308.1668
andreas.wiederhold@sartorius.com

Branche: Biotechnology
ISIN: DE0007165607
WKN: 716560
Index: CDAX, Prime All Share, Technologie All Share
Börsen: Frankfurter Wertpapierbörse / official dealing/prime standard
Börse Berlin-Bremen / free trade
Hamburger Wertpapierbörse / free trade
Baden-Württembergische Wertpapierbörse / free trade
Börse Düsseldorf / free trade
Bayerische Börse / free trade
Niedersächsische Börse zu Hannover / official dealing